Marc Funk, Chief Executive Officer at Recipharm, said: “We’re delighted to welcome GenIbet and its talented team of experts. The deal will provide Recipharm with a platform from which to build its capabilities in new Biologics modalities, leveraging GenIbet’s expertise in viral vectors and vaccines. ![]() Through its relationship with not-for-profit research organisation Ibet, the CDMO offers deep scientific expertise and novel solutions where no established production route exists. GenIbet currently works with customer projects in the preclinical and Phase 1 stages and has a track record of developing novel production processes. The acquisition forms part of Recipharm’s strategy to grow in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs. Global contract development and manufacturing organisation (CDMO), Recipharm, has today announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |